02172 MICROPORT NEURO
- 8.930
- -0.550-5.80%
MICROPORT NEURO News
Minimally Invasive Brain Science (02172.HK): Steady improvement in performance, consolidation of leading position in domestic production of neurological intervention
Minimally Invasive Brain Science (02172.HK): Adjusted profit exceeds expectations, focusing on new domestic products and overseas sales
Minimally Invasive Brain Science (2172.HK): Benefiting from steady revenue growth and reduced expense ratios, net profit is expected to achieve high growth in 2024
Minimally Invasive Brain Science (02172.HK): Steady Improvement in Performance, Continued Outstanding Performance of Core Products*Luo Jiarong* Announcement Comment
Minimally Invasive Brain Science (02172.HK): High profit growth can be expected to accelerate in 2024
Minimally Invasive Brain Science (2172.HK): Leading domestic Shinsuke collection and new products with both growth and certainty drive performance growth
Minimally Invasive Brain Science (02172.HK): Internationalization Accelerates and Enhances Continued Outstanding Performance of Core Products
Minimally Invasive Brain Science (02172.HK): 2023H1 turns a loss into profit, and the launch volume of many major products can be expected
CICC: Maintaining Minimally Invasive Brain Science (02172) “Outperform the Industry” Rating Target Price of HK$18
Minimally Invasive Brain Science (02172.HK): Leading Domestic Neural Interventions Lead the Trend of Imported Substitution
Minimally Invasive Brain Science (02172.HK): Accelerated revenue growth can be expected throughout the year
Minimally Invasive Brain Science (02172.HK): Complete supplies for atrial fibrillation and rapid performance
Minimally Invasive Brain Science (02172.HK): Leading Neural Interventional Company with Accumulated Hair
Minimally Invasive Neuroscience (2172.HK): China's pioneer in neurointerventional medical devices
IPO Purchase Guide: Minimally Invasive Brain Science (2172.HK)
Analysis
Price Target
No Data
